Corbus Pharmaceuticals Holdings, Inc. reported a net loss of $20.6 million for the fourth quarter of 2025 and a full‑year net loss of $78.5 million, a widening of the loss compared with prior periods. Operating expenses for the quarter rose to $22.0 million, driven largely by increased clinical development costs. Cash and cash equivalents stood at $163.3 million as of December 31 2025, bolstered by a $75 million public offering completed in the quarter.
The company posted a GAAP earnings‑per‑share loss of $1.25, beating the consensus estimate of $1.61 by $0.36. The beat was largely attributable to disciplined cost management that offset the higher R&D spend, allowing the company to narrow its quarterly loss relative to expectations.
Revenue for the quarter was $0, in line with expectations for a clinical‑stage biopharmaceutical company that has not yet generated sales. The absence of revenue is consistent with the company’s focus on advancing its pipeline rather than generating product sales.
Management highlighted encouraging data from its lead antibody‑drug conjugate, CRB‑701, and its obesity candidate, CRB‑913. CEO Yuval Cohen said, “Our encouraging data readouts for CRB‑701 and CRB‑913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026. This summer we anticipate key data readouts for both programs that we expect will elucidate their differentiated efficacy and safety profiles, as well as potential clinical utility and commercial opportunities.” He added that the clinical responses in head‑and‑neck and cervical cancer patients with CRB‑701 and the rapid weight loss and favorable gastrointestinal tolerability seen with CRB‑913 underscore the potential of these assets.
The $75 million equity raise increased the company’s cash balance to $163.3 million, providing a runway through 2028. Corbus is concentrating resources on CRB‑701 and CRB‑913, while deprioritizing CRB‑601. The company’s focus on these two programs reflects a strategic narrowing of its pipeline to accelerate development and potential partnership opportunities.
Investors reacted positively to the earnings release, citing the EPS beat and the encouraging pipeline data as key drivers of the favorable reception.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.